{
  "kind": "all",
  "value": "all",
  "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations",
  "filters": {
    "documentKinds": [],
    "sourceTypes": [],
    "orientations": []
  },
  "total": 319975,
  "page": 7380,
  "pageSize": 30,
  "pageCount": 10666,
  "rows": [
    {
      "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
      "docSlug": "a4fc5169399f8913c54f14d18031629c",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 18,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The chart demonstrates the mechanism of action: rapid cell expansion followed by clearance within 30 days, correlating with disease marker reduction.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/18",
      "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
      "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-18",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 22,
          "from": 18,
          "beatId": "b9896073-6be4-4e40-b3ed-41f8f273601a",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Traction",
          "beatSlug": null,
          "evidence": "Clinical results and progress are highlighted.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
      "docSlug": "a4fc5169399f8913c54f14d18031629c",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 19,
      "slideType": "problem_statement",
      "function": "frame_problem",
      "notes": "The slide uses a causal chain framework to link cellular pathology to systemic organ damage.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/19",
      "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
      "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-19",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 22,
          "from": 18,
          "beatId": "b9896073-6be4-4e40-b3ed-41f8f273601a",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Traction",
          "beatSlug": null,
          "evidence": "Clinical results and progress are highlighted.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
      "docSlug": "a4fc5169399f8913c54f14d18031629c",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 20,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The slide uses a grouped bar chart format to compare clinical outcomes across different therapeutic agents.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/20",
      "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
      "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-20",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 22,
          "from": 18,
          "beatId": "b9896073-6be4-4e40-b3ed-41f8f273601a",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Traction",
          "beatSlug": null,
          "evidence": "Clinical results and progress are highlighted.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
      "docSlug": "a4fc5169399f8913c54f14d18031629c",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 21,
      "slideType": "comparison_table",
      "function": "compare_peers",
      "notes": "The slide uses a table to contrast treatment efficacy and patient growth across disease stages.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/21",
      "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
      "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-21",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 22,
          "from": 18,
          "beatId": "b9896073-6be4-4e40-b3ed-41f8f273601a",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Traction",
          "beatSlug": null,
          "evidence": "Clinical results and progress are highlighted.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
      "docSlug": "a4fc5169399f8913c54f14d18031629c",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 22,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The slide explicitly notes that these are cross-trial comparisons and not head-to-head results.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/22",
      "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
      "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-22",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 22,
          "from": 18,
          "beatId": "b9896073-6be4-4e40-b3ed-41f8f273601a",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Traction",
          "beatSlug": null,
          "evidence": "Clinical results and progress are highlighted.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
      "docSlug": "a4fc5169399f8913c54f14d18031629c",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 23,
      "slideType": "roadmap",
      "function": "plan_implementation",
      "notes": "Includes FDA approval precedents as a footnote to justify the clinical strategy.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/23",
      "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
      "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-23",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 27,
          "from": 23,
          "beatId": "8a2b8975-ade2-4ded-a004-449e34d77602",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Roadmap",
          "beatSlug": null,
          "evidence": "The clinical development plan and upcoming catalysts are outlined.",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
      "docSlug": "a4fc5169399f8913c54f14d18031629c",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 24,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "Uses a visual icon-grid to represent market expansion.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/24",
      "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
      "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-24",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 29,
          "from": 24,
          "beatId": "fd3d2933-01c8-4f4e-b2ff-7ac84717f569",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Market Sizing",
          "beatSlug": "sequoia-pitch-market-size",
          "evidence": "The market opportunities for Immix Biopharma's therapies are discussed.",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        },
        {
          "to": 27,
          "from": 23,
          "beatId": "8a2b8975-ade2-4ded-a004-449e34d77602",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Roadmap",
          "beatSlug": null,
          "evidence": "The clinical development plan and upcoming catalysts are outlined.",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
      "docSlug": "a4fc5169399f8913c54f14d18031629c",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 25,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Includes detailed clinical trial citations in the footer.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/25",
      "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
      "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-25",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 29,
          "from": 24,
          "beatId": "fd3d2933-01c8-4f4e-b2ff-7ac84717f569",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Market Sizing",
          "beatSlug": "sequoia-pitch-market-size",
          "evidence": "The market opportunities for Immix Biopharma's therapies are discussed.",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        },
        {
          "to": 27,
          "from": 23,
          "beatId": "8a2b8975-ade2-4ded-a004-449e34d77602",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Roadmap",
          "beatSlug": null,
          "evidence": "The clinical development plan and upcoming catalysts are outlined.",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
      "docSlug": "a4fc5169399f8913c54f14d18031629c",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 26,
      "slideType": "roadmap",
      "function": "plan_implementation",
      "notes": "The slide uses a two-column layout to separate milestones by drug candidate.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/26",
      "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
      "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-26",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 29,
          "from": 24,
          "beatId": "fd3d2933-01c8-4f4e-b2ff-7ac84717f569",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Market Sizing",
          "beatSlug": "sequoia-pitch-market-size",
          "evidence": "The market opportunities for Immix Biopharma's therapies are discussed.",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        },
        {
          "to": 27,
          "from": 23,
          "beatId": "8a2b8975-ade2-4ded-a004-449e34d77602",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Roadmap",
          "beatSlug": null,
          "evidence": "The clinical development plan and upcoming catalysts are outlined.",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
      "docSlug": "a4fc5169399f8913c54f14d18031629c",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 27,
      "slideType": "roadmap",
      "function": "show_traction",
      "notes": "The slide uses a standard pharmaceutical pipeline table format, categorizing by clinical vs preclinical status and highlighting specific regulatory designations and trial results.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/27",
      "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
      "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-27",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 29,
          "from": 24,
          "beatId": "fd3d2933-01c8-4f4e-b2ff-7ac84717f569",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Market Sizing",
          "beatSlug": "sequoia-pitch-market-size",
          "evidence": "The market opportunities for Immix Biopharma's therapies are discussed.",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        },
        {
          "to": 27,
          "from": 23,
          "beatId": "8a2b8975-ade2-4ded-a004-449e34d77602",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Roadmap",
          "beatSlug": null,
          "evidence": "The clinical development plan and upcoming catalysts are outlined.",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
      "docSlug": "a4fc5169399f8913c54f14d18031629c",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 28,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "Includes a comparative table of clinical outcomes (ORR/CR) for NXC-201 vs competitors.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/28",
      "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
      "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-28",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 29,
          "from": 24,
          "beatId": "fd3d2933-01c8-4f4e-b2ff-7ac84717f569",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Market Sizing",
          "beatSlug": "sequoia-pitch-market-size",
          "evidence": "The market opportunities for Immix Biopharma's therapies are discussed.",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
      "docSlug": "a4fc5169399f8913c54f14d18031629c",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 29,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "The slide uses a visual wave/area chart metaphor to represent market segments and their respective valuations.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/29",
      "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
      "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-29",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 29,
          "from": 24,
          "beatId": "fd3d2933-01c8-4f4e-b2ff-7ac84717f569",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Market Sizing",
          "beatSlug": "sequoia-pitch-market-size",
          "evidence": "The market opportunities for Immix Biopharma's therapies are discussed.",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
      "docSlug": "a4fc5169399f8913c54f14d18031629c",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 30,
      "slideType": "section_divider",
      "function": "transition",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/30",
      "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
      "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-30",
      "loopMatches": [
        {
          "to": 30,
          "from": 30,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "0b3e815d-9465-48f9-910b-a6943e26c1a5",
          "evidence": "The market sizing section discusses the potential for Immix Biopharma's therapies.",
          "position": 2,
          "objective": "What are the opportunities for growth and expansion?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.6,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
      "docSlug": "a4fc5169399f8913c54f14d18031629c",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 31,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/31",
      "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
      "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-31",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
      "docSlug": "a4fc5169399f8913c54f14d18031629c",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 32,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The chart uses a grouped bar structure to compare NXC-201 (green) against other therapies (blue/red) categorized by prior BCMA treatment status.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/32",
      "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
      "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-32",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
      "docSlug": "a4fc5169399f8913c54f14d18031629c",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 33,
      "slideType": "comparison_table",
      "function": "compare_peers",
      "notes": "The table compares NXC-201 against various CAR-T therapies, highlighting patient characteristics, efficacy (ORR, CR), and safety (ICANS, CRS) metrics.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/33",
      "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
      "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-33",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
      "docSlug": "a4fc5169399f8913c54f14d18031629c",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 34,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The slide uses a side-by-side comparison of two disease indications, showing clinical results, relevant competitor benchmarks, and market size.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/34",
      "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
      "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-34",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
      "docSlug": "a4fc5169399f8913c54f14d18031629c",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 35,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The chart demonstrates deepening clinical response over time for NXC-201 therapy.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/35",
      "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
      "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-35",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
      "docSlug": "a4fc5169399f8913c54f14d18031629c",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 36,
      "slideType": "appendix_data",
      "function": "analyze_data",
      "notes": "The table displays clinical trial data for NXC-201, specifically focusing on safety profiles and management interventions.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/36",
      "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
      "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-36",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
      "docSlug": "a4fc5169399f8913c54f14d18031629c",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 37,
      "slideType": "comparison_table",
      "function": "compare_peers",
      "notes": "The table highlights specific clinical safety metrics including onset and duration for CRS and ICANS, as well as the use of Tocilizumab and Dexamethasone.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/37",
      "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
      "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-37",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
      "docSlug": "a4fc5169399f8913c54f14d18031629c",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 38,
      "slideType": "appendix_methodology",
      "function": "plan_implementation",
      "notes": "The slide uses a step-wise diagram to illustrate dose escalation in a clinical trial setting.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/38",
      "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
      "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-38",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
      "docSlug": "a4fc5169399f8913c54f14d18031629c",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 39,
      "slideType": "section_divider",
      "function": "transition",
      "notes": "The slide features a scientific illustration of cellular structures, likely representing the drug's mechanism of action or target environment.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/39",
      "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
      "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-39",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
      "docSlug": "a4fc5169399f8913c54f14d18031629c",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 40,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "Includes scientific diagrams of molecular pathways, penetration depth charts, and efficacy metrics.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/40",
      "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
      "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-40",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
      "docSlug": "a4fc5169399f8913c54f14d18031629c",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 41,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Slide contains three distinct charts comparing IMX-110 against standard of care in mouse models.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/41",
      "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
      "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-41",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
      "docSlug": "a4fc5169399f8913c54f14d18031629c",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 42,
      "slideType": "other",
      "function": "illustrate_case",
      "notes": "Includes a process flow diagram illustrating the mechanism of action of IMX-110 in tumor microenvironments.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/42",
      "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
      "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-42",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
      "docSlug": "a4fc5169399f8913c54f14d18031629c",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 43,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Includes survival curves (Kaplan-Meier style), median survival bar charts, and bioluminescence imaging of tumor activity.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/43",
      "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
      "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-43",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
      "docSlug": "a4fc5169399f8913c54f14d18031629c",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 44,
      "slideType": "section_divider",
      "function": "transition",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/44",
      "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
      "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-44",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
      "docSlug": "a4fc5169399f8913c54f14d18031629c",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 45,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The slide compares sarcoma patients against non-sarcoma patients using line charts for lesion size change and a bar chart for best percentage change.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/45",
      "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
      "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-45",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
      "docSlug": "a4fc5169399f8913c54f14d18031629c",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 46,
      "slideType": "problem_statement",
      "function": "frame_problem",
      "notes": "The bubble chart maps mPFS against patient treatment history; the table highlights poor outcomes and high toxicity across lines of therapy.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/46",
      "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
      "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-46",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
      "docSlug": "a4fc5169399f8913c54f14d18031629c",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-11-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 47,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The slide presents clinical data for a small sample size (n=4).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/47",
      "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
      "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-47",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    }
  ]
}